Evidence map›Paper›PMID 37286807›Full record

ArticleNature medicine2023

Observational studies must be reformed before the next pandemic.

Emily E Ricotta, Annette Rid, I Glenn Cohen, Nicholas G Evans

Abstract read
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Time to publication for results of clinical trials.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Data-Driven Insights in Healthcare.Healthcare (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Evidence for the Efficacy of COVID-19 Convalescent Plasma.Current topics in microbiology and immunology · 2025
    Review
  8. Clinical study types and guidance for their correct post-pandemic interpretation.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily E RicottaEpidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA. emily.ricotta@nih.gov.ORCID http://orcid.org/0000-0001-9928-8275
Annette RidDepartment of Bioethics, Clinical Center, NIH, Bethesda, MD, USA.
I Glenn CohenPetrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0223-3305
Nicholas G EvansDepartment of Philosophy, University of Massachusetts Lowell, Lowell, MA, USA.ORCID http://orcid.org/0000-0002-3330-0224

Funding

The study and improvement of data collection and management for infectious diseases and immunodeficienciesZIAAI001367 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RICOTTA, EMILY · 2023 to 2024
$292k
Intramural NIH HHS ZIA AI001367
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Observational Studies as TopicPandemics

Identifiers

PMID37286807
PMCPMC10527502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.